Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Elmiron 100 Mg Caps 100 By J O M Pharma.

Image 0 of Elmiron 100 Mg Caps 100 By J O M Pharma.Image 1 of Elmiron 100 Mg Caps 100 By J O M Pharma.

Elmiron 100 Mg Caps 100 By J O M Pharma.

Call for Price

Elmiron 100 Mg Caps 100 By J O M Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD4279998/RXB10000344/RXa009803/RXA321982
Size : 100
Selling UoM : EA
NDC: 50458-0098-01
UPC Barcode : 350458098013
Supplier: 0050000511 J-O-M PHARM SERVICES
Supplier Material : 009801
Generic Code : 021175 PENTOSAN POLYSULFATE SODIUM ORAL CAPSULE
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX

Have a question?

  Call for Price

Product Description.:

BNP 7600, BNP 7600
capsule , white , oblong oblong
OpaqueBlack ink

Pentosan polysulfate sodium is a semi-synthetically produced heparin-like macro molecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water to 50% at pH 6.

ELMIRON? is supplied in white opaque hard gelatin capsules containing 100 mg pentosan polysulfate sodium, microcrystalline cellulose, and magnesium stearate. It also contains pharmaceutical glaze (modified) in SD-45, synthetic black iron oxide, FD&C Blue No. 2 aluminum lake, FD&C Red No. 40 aluminum lake, FD&C Blue No. 1 aluminum lake, D&C Yellow No. 10 aluminum lake, n-butyl alcohol, propylene glycol, SDA-3A alcohol, and titanium dioxide. It is formulated for oral use.

INDICATIONS

ELMIRON? (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

SIDE EFFECTS

ELMIRON? was evaluated in clinical trials in a total of 2627 patients (2343 women, 262 men, 22 unknown) with a mean age of 47 [range 18 to 88 with 581 (22%) over 60 years of age]. Of the 2627 patients, 128 patients were in a 3 month trial and the remaining 2499 patients were in a long term, unblinded trial.

Deaths occurred in 6/2627 (0.2%) patients who received the drug over a period of 3 to 75 months. The deaths appear to be related to other concurrent illnesses or procedures, except in one patient for whom the cause was not known.

Serious adverse events occurred in 33/2627 (1.3%) patients. Two patients had severe abdominal pain or diarrhea and dehydration that required hospitalization. Because there was not a control group of patients with interstitial cystitis who were concurrently evaluated, it is difficult to determine which events are associated with ELMIRON? and which events are associated with concurrent illness, medicine, or other factors.